Beyond The Numbers: 8 Analysts Discuss Novo Nordisk Stock

Analysts' ratings for Novo Nordisk (NYSE:NVO) over the last quarter vary from bullish to bearish, as provided by 8 analysts.Summarizing their recent assessments, the table below illustrates the evolvi

Benzinga00:01

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:NVO) with a Overweight and maintains $160 price target.

BenzingaJul 1 23:17

Novo Nordisk Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 10.43% Cantor Fitzgerald $160 → $160 Reiterates Overweight → Overweight 06/25/2024 12.5% BMO Ca

BenzingaJul 1 23:15

Novo Nordisk A/S - Share Repurchase Programme

Yahoo FinanceJul 1 21:19

US drug prices have skyrocketed by 40%! Over 30% of people are 'hopeless sighs' about the high cost of drugs, and Biden is urgently pushing measures to address it.

In the past decade, prescription drug prices in the USA have skyrocketed by nearly 40%, far exceeding inflation rates, resulting in about one-third of Americans being unable to purchase medicine from pharmacies.

Zhitong FinanceJul 1 14:55

Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2

Seeking AlphaJul 1 08:30